Logo image of NUVL

NUVALENT INC-A (NUVL) Stock Fundamental Analysis

NASDAQ:NUVL - Nasdaq - US6707031075 - Common Stock - Currency: USD

79.49  -2.9 (-3.52%)

After market: 79.49 0 (0%)

Fundamental Rating

3

Taking everything into account, NUVL scores 3 out of 10 in our fundamental rating. NUVL was compared to 572 industry peers in the Biotechnology industry. NUVL has a great financial health rating, but its profitability evaluates not so good. NUVL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NUVL had negative earnings in the past year.
NUVL had a negative operating cash flow in the past year.
NUVL had negative earnings in each of the past 5 years.
NUVL had a negative operating cash flow in each of the past 5 years.
NUVL Yearly Net Income VS EBIT VS OCF VS FCFNUVL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

The Return On Assets of NUVL (-18.87%) is better than 79.40% of its industry peers.
With an excellent Return On Equity value of -20.01%, NUVL belongs to the best of the industry, outperforming 85.26% of the companies in the same industry.
Industry RankSector Rank
ROA -18.87%
ROE -20.01%
ROIC N/A
ROA(3y)-16.66%
ROA(5y)-109.04%
ROE(3y)-17.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NUVL Yearly ROA, ROE, ROICNUVL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 200 -200 400 600

1.3 Margins

NUVL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NUVL Yearly Profit, Operating, Gross MarginsNUVL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for NUVL has been increased compared to 1 year ago.
There is no outstanding debt for NUVL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NUVL Yearly Shares OutstandingNUVL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M
NUVL Yearly Total Debt VS Total AssetsNUVL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 49.95 indicates that NUVL is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 49.95, NUVL belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
There is no outstanding debt for NUVL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 49.95
ROIC/WACCN/A
WACCN/A
NUVL Yearly LT Debt VS Equity VS FCFNUVL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

NUVL has a Current Ratio of 23.07. This indicates that NUVL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NUVL (23.07) is better than 95.56% of its industry peers.
NUVL has a Quick Ratio of 23.07. This indicates that NUVL is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 23.07, NUVL belongs to the best of the industry, outperforming 95.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 23.07
Quick Ratio 23.07
NUVL Yearly Current Assets VS Current LiabilitesNUVL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for NUVL have decreased strongly by -70.94% in the last year.
EPS 1Y (TTM)-70.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-116.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NUVL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.59% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-85.02%
EPS Next 2Y-45.76%
EPS Next 3Y-29.82%
EPS Next 5Y13.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NUVL Yearly Revenue VS EstimatesNUVL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
NUVL Yearly EPS VS EstimatesNUVL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NUVL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUVL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUVL Price Earnings VS Forward Price EarningsNUVL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUVL Per share dataNUVL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

NUVL's earnings are expected to decrease with -29.82% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.76%
EPS Next 3Y-29.82%

More info and screens

0

5. Dividend

5.1 Amount

NUVL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVALENT INC-A

NASDAQ:NUVL (2/21/2025, 8:00:01 PM)

After market: 79.49 0 (0%)

79.49

-2.9 (-3.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners104.91%
Inst Owner Change-97.93%
Ins Owners3.39%
Ins Owner Change2.99%
Market Cap5.65B
Analysts86
Price Target117.34 (47.62%)
Short Float %9.45%
Short Ratio11.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-23.51%
Min EPS beat(2)-33.94%
Max EPS beat(2)-13.07%
EPS beat(4)1
Avg EPS beat(4)-11.9%
Min EPS beat(4)-33.94%
Max EPS beat(4)0.55%
EPS beat(8)4
Avg EPS beat(8)-4.74%
EPS beat(12)7
Avg EPS beat(12)-1.48%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.4%
PT rev (3m)-0.4%
EPS NQ rev (1m)2.9%
EPS NQ rev (3m)2.9%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)-12.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.04
P/tB 5.04
EV/EBITDA N/A
EPS(TTM)-3.47
EYN/A
EPS(NY)-4.59
Fwd EYN/A
FCF(TTM)-2.16
FCFYN/A
OCF(TTM)-2.16
OCFYN/A
SpS0
BVpS15.78
TBVpS15.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.87%
ROE -20.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-16.66%
ROA(5y)-109.04%
ROE(3y)-17.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.07
Quick Ratio 23.07
Altman-Z 49.95
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-70.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-116.95%
EPS Next Y-85.02%
EPS Next 2Y-45.76%
EPS Next 3Y-29.82%
EPS Next 5Y13.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-81.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-79.74%
EBIT Next 3Y-35.96%
EBIT Next 5YN/A
FCF growth 1Y-154.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-154.86%
OCF growth 3YN/A
OCF growth 5YN/A